SMMT
Summit Therapeutics Inc.
NASDAQ · Healthcare · Biotechnology · US
$17.50
+2.18%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−15.5x
Market Cap
$13.96B
MomentumView details →
1D Return
+2.18%
YTD Return
−0.71%
RSI (14)
70.2
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−15.5x
Market Cap
$13.96B
RSI (14)
70.2
MomentumView details →
1D Return
+2.18%
YTD Return
−0.71%
SummaryUpdated Jun 1, 2026
Summit Therapeutics Inc. (NASDAQ:SMMT) is a biopharmaceutical company founded in 2003 and headquartered in Cambridge, Massachusetts. Originally focused on developing treatments for infectious diseases, the company underwent a strategic transformation in 2022 when it pivoted entirely to oncology. Summit acquired the rights to develop and commercialize ivonescimab, a promising cancer immunotherapy, through a landmark $500 million licensing agreement with Chinese biotech company Akeso. The company is now focused exclusively on advancing this bispecific antibody through late-stage clinical trials for various cancer indications, particularly non-small cell lung cancer.
Similar companies
Latest newsMore news →
Summit Therapeutics stock jumped 17% after ivonescimab showed a significant overall survival benefit over Keytruda in a China phase III lung cancer study.4h agoAkeso Inc. announced positive overall survival results from the Phase III HARMONi-2 study, showing ivonescimab monotherapy significantly improved OS versus pembrolizumab in PD-L1-positive advanced NSCLC.2d agoAkeso Inc. announced positive topline results from the Phase III HARMONi-GI1 study of ivonescimab plus chemotherapy in advanced biliary tract cancer, showing statistically significant overall survival benefit versus durvalumab plus chemotherapy.10d ago